About the Lung Adenocarcinoma Session
Lung adenocarcinoma, a type of non-small cell lung cancer (NSCLC), poses significant challenges in cancer research. Despite advancements in treatment, its prognosis remains poor, necessitating ongoing research efforts. Scientists are exploring various fronts, from molecular pathways to immunotherapy, to devise targeted and effective treatments. Understanding the genetic mutations driving adenocarcinoma formation is crucial for personalized therapies. Additionally, research focuses on identifying biomarkers for early detection and prognosis prediction. Novel immunotherapies, such as checkpoint inhibitors, offer promising avenues by harnessing the body's immune system to fight cancer cells. Advancements in imaging technologies aid in precise diagnosis and monitoring of treatment response. Collaborative efforts across disciplines are essential to unraveling the complexities of lung adenocarcinoma, ultimately leading to improved outcomes for patients.
Topics Covered in Lung Adenocarcinoma
EGFR Mutations
ALK Rearrangements
KRAS Inhibition
Ground-Glass Nodules
Histologic Patterns
Checkpoint Inhibitors
Related Scientific Sessions at CIOC 2027
Why Attend the Lung Adenocarcinoma Conference 2027
Earn CPD Credit
Sessions are CPD-accredited; certificates issued to every registered delegate within two weeks of the conference.
Present Your Research
Oral and poster slots for original Lung Adenocarcinoma work, reviewed by the scientific committee.
Network Globally
Meet oncologists, cancer researchers, and clinical specialists from around the world across three days.
Publish & Get Indexed
Accepted abstracts appear in the indexed conference proceedings with a citable DOI.
Learn from Keynotes
Plenary lectures from leading voices shaping Lung Adenocarcinoma research and practice.
Hybrid Flexibility
Attend in person in Singapore or join virtually — same programme, same certificate.
Join CIOC 2027 for the Lung Adenocarcinoma track
Oral and poster slots for your work — in person in Singapore or online. Not presenting? Attend as a delegate to learn from the field.
Lung Adenocarcinoma Conference 2027 — FAQs
What is the Lung Adenocarcinoma track at CIOC 2027?
The Lung Adenocarcinoma track is a dedicated stream within CIOC 2027 covering the latest research, clinical innovation, and best practice in Lung Adenocarcinoma. It brings together researchers, educators, and practitioners for oral presentations, posters, and discussion.
Who should attend the Lung Adenocarcinoma sessions?
Cancer researchers and clinicians, educators and students with an interest in Lung Adenocarcinoma are all welcome — whether presenting or attending.
Can I present my research in the Lung Adenocarcinoma track?
Yes. Submit an abstract for oral or poster presentation. All submissions are peer-reviewed by the scientific committee; accepted abstracts appear in the indexed proceedings.
Is virtual attendance available for Lung Adenocarcinoma sessions?
Yes. CIOC 2027 is a hybrid conference — attend the Lung Adenocarcinoma track in person in Singapore or join live online, with on-demand access afterward.
Join the CIOC 2027 delegation
Singapore · March 15–17, 2027· Hybrid · in-person & virtual
Attend without presenting.